title: The use of dexrazoxane for the prevention of anthracycline extravasation injury.
abstract: BACKGROUND
  The use of the anthracycline anticancer drugs doxorubicin, daunorubicin, epirubicin and idarubicin sometimes results in accidental extravasation injury and can be a serious complication of their use.
  
  
  OBJECTIVE
  The object of this review was to evaluate the preclinical and clinical literature on the use of dexrazoxane in preventing anthracycline-induced extravasation injury.
  
  
  METHODS
  A review of the literature was carried out using PubMed.
  
  
  CONCLUSIONS
  Dexrazoxane, which is clinically used to reduce doxorubicin-induced cardiotoxicity, has been shown in two clinical studies and in several case reports to be highly efficacious in preventing anthracycline-induced extravasation injury. Dexrazoxane is a prodrug analog of the metal chelator EDTA that likely acts by removing iron from the iron-anthracycline complex, thus preventing formation of damaging reactive oxygen species.
authors.affiliation: Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada. B_Hasinoff@UManitoba.ca
authors.forename: Brian B
authors.initials: BB
authors.lastname: Hasinoff
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D011929:Razoxane / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D002316:Cardiotonic Agents; D011929:Razoxane